Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-85
SponsorUniversity Medical Center Goettingen
About this trial
The trial aims at the construction and validation of an accurate, affordable and simple prognostic tool to be used in everyday clinical practice, which allows the early and reliable identification of DLBCL patients who have a very high risk of treatment failure following R-CHOP/-like first-line therapy.
Eligibility criteria
Qualifiers
Histological diagnosis of DLBCL&LBCL
Planned treatment with guideline-based first-line therapy
Patient's consent
All genders, Patient age ≥ 18 years
Disqualifiers
Treatment with R-CHOP/-like regimens already started
Relationship of dependence/ direct employment with the investigator
Active HIV-infection
Presence history of other active cancers (with the exception of basal cell carcinoma of the skin)
Trial design
Treatments tested in this trial
- no intervention
Treatment groups
No treatment groups listed
Sponsors and collaborators
University Medical Center Goettingen
Lead sponsor
Charite University, Berlin, Germany
Collaborator
Wuerzburg University Hospital
Collaborator
University Hospital Ulm
Collaborator
University of Leipzig
Collaborator
University Hospital Regensburg
Collaborator
University Hospital Freiburg
Collaborator
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Collaborator
University of Kiel
Collaborator
University Hospital, Essen
Collaborator
Source ClinicalTrials.gov